Gastroesophageal Junction Adenocarcinoma Clinical Trials in Shanghai, Shanghai Municipality
4 recruitingShanghai, Shanghai Municipality, China
Showing 1–4 of 4 trials
Recruiting
Phase 2
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.258 enrolled1 locationNCT05671822
Recruiting
Phase 2Phase 3
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled12 locationsNCT06221748
Recruiting
Phase 1
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
Pancreatic CancerGastric CancerGastroesophageal Junction Adenocarcinoma+1 more
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled1 locationNCT05472857
Recruiting
Phase 3
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.360 enrolled1 locationNCT06123494